Purpose:
The study aims to investigate how Filgotinib affects proteins and micro-RNA in the blood of patients with rheumatoid arthritis. This could help understand its impact on inflammation and bone health in these patients.
Study Design:
This is a single-center, prospective randomized study.
Rheumatoid arthritis (RA) according to ACR/EULAR 2010 criteria with active disease (Disease Activity Score 28-joints C-reactive protein [DAS28 CRP] >5.1 and/or Clinical Disease Activity Index [CDAI] >22)
Age > 18, <65 years
Patients for whom treatment with filgotinib or adalimumab might be planned
History of major cardiovascular events or stroke
History of venous thromboembolism
Active smokers or past smokers >10 pack/years
History of fragility fractures or severe osteoporosis (T score at total hip or femoral neck or lumbar spine ≤3.5)